mercredi 3 mai 2017

Onco Actu du 3 mai 2017

1. Biologie

This could be the future of how doctors view cancer [Cancer Research UK]

3.1.1 Tabac - e-cigs

FDA delays enforcement of stricter standards for e-cigarette, cigar industry [Washington Post]

5. Traitements

New Gene Therapy Shrinks Aggressive Tumors in Mice [The Scientist]

5.10 Traitements - Essais

FDA and NIH Release Final Template for Clinical Trial Protocols [FDA Voice]

5.12 Immunothérapies

First extensive immune profiling of sarcomas shows some likely susceptible to immunotherapy [Fred Hutch]

Testing a new immunotherapy treatment for neuroblastoma [Cancer Research UK]

5.12.2 Immunothérapies - CAR-T

Novartis licenses CAR-T patents from bluebird, Celyad [FierceBiotech]

bluebird bio Licenses Lentiviral Vector Patent Rights for Development and Commercialization of Cell Therapies [bluebird]

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents [Celyad]

Novartis takes the long view on CAR-T, grabbing licenses on new tech for next-gen therapies [EndPoints]

5.2.2 Pharma - Fusions & Acquisitions

Is Pfizer really weighing a BMS buy? Clues from Q1's earnings call say it just may be [FiercePharma]

5.2.3 Pharma - économie

Gardasil posts big Q1 beat to push Merck vaccines to 21% growth [FiercePharma]

Merck's Cancer Sales Soar In White-Hot Market [Forbes]

6. Lutte contre les cancers

How Pediatric and Canine Cancer Similarities Can Help Both Children and Pets [Dana-Farber]

NIH to limit the amount of grant money a scientist can receive [Nature]

6.10 Politiques

Brexit regulatory uncertainty 'threatens UK med tech' [Reuters]

6.12 Ethique

The Complex and Multifaceted Aspects of Conflicts of Interest [JAMA]

Limits on doctor-drug rep interactions tied to prescribing changes [Reuters]

6.5 Médecines alternatives

Old wine poured into a newer skin: The Society for Integrative Oncology updates its clinical guidelines for breast cancer [Respectful Insolence]

6.6 Publications

Peer review in 2030: New report hopes it’s faster, more transparent, and more diverse [Retraction Watch]

Researchers frustrated by Italian misconduct probe [Nature]